Chorom Pak

Chorom Pak has been working in the biotech industry since 2009. In 2008, they began working as a Graduate Research Assistant at the University of Wisconsin-Madison, where their thesis work focused on elucidating the factor(s) activating the proteasome-inhibitor resistant (PIR) NF-κB pathway in multiple myeloma (MM) drug resistance. In 2014, they continued their work at the University of Wisconsin-Madison as a Post-Doctoral Associate. In 2015, they joined Cellectar Biosciences, Inc. as a Research and Clinical Development Lead and Biologist. In 2017, they founded Lynx Biosciences (LynxBio), a San Diego-based biotech that generates unparalleled biological insights by combining primary cell co-culture assays with automated microfluidics, high-content imaging, and integrative multi-omic readouts. Finally, they have been an Instructor at The Princeton Review since 2009.

Chorom Pak received their B.A. in Cell and Molecular Biology from Skidmore College in 2008. Chorom then pursued a Ph.D. in Molecular and Cellular Pharmacology from the UW School of Medicine and Public Health, which they completed in 2013. In 2011, they also took a course in Entrepreneurship at the Wisconsin School of Business.